Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula RegisterShow others and affiliations
2017 (English)In: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 95, no 8, p. 787-795Article in journal (Refereed) Published
Abstract [en]
Purpose: To present Swedish Macula Register (SMR) data regarding treatment of neovascular age-related macular degeneration (AMD) in clinical practice since 2008.
Methods: A retrospective register-based study was conducted. Evaluation of baseline demographics, visual outcome and number of injections during this period is presented.
Results: Mean age at diagnosis was 79(SD) 8years; 65% were female. The proportion of patients with <2months' duration of symptoms increased from 26% in 2008 to 41% in 2014 (p=0.001). Mean visual acuity (VA) at baseline increased from 54.3 +/- 15.0 early treatment diabetic retinopathy study (ETDRS) letters in 2008 to 57.8 +/- 15.6 letters in 2014 (CI95 2.6; 4.3; p<0.001). Mean VA after 1year of treatment increased from 57.8 +/- 17.7 ETDRS letters for patients who started the treatment in 2008 to 62.8 +/- 16.4 ETDRS letters in patients starting treatment in 2014 (CI95 2.67; 4.64; p<0.001). During all study years, the proportion of patients with an improvement in VA of between 5 and 15 letters was around 30%, while 14% had VA improvement of more than 15 letters. The mean number of injections during the first treatment year increased from 4.3 +/- 1.9 in 2008 to 5.9 +/- 2.9 in 2014 (CI95 1.40; 1.67; p<0.001). Seven-year follow-up of 322 eyes showed a mean change of -1 letters from baseline, with a mean of 21 injections for the entire period.
Conclusion: The duration of symptoms before treatment decreased, while VA at baseline and after 1year of treatment increased over the years and so did the number of injections. Long-term follow-up demonstrated stable VA.
Place, publisher, year, edition, pages
2017. Vol. 95, no 8, p. 787-795
Keywords [en]
age-related macular degeneration, anti-vascular endothelial growth factor, anti-VEGF, ETDRS, neovascular AMD, Swedish Macula Register
National Category
Ophthalmology
Identifiers
URN: urn:nbn:se:uu:diva-343909DOI: 10.1111/aos.13539ISI: 000417645900022PubMedID: 28834299OAI: oai:DiVA.org:uu-343909DiVA, id: diva2:1187151
2018-03-022018-03-022018-03-08Bibliographically approved